Pharmacovigilance and Drug Safety Software Market by Product Type, Distribution Channel, End User 2024-2032
                     Global Pharmacovigilance 
and Drug Safety Software 
Market Research and 
Forecast Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
A cc o r d i ng  t o  t h e  l a te s t  r e po r t  b y  I M A R C  G r o up ,  t i t l e d  " P h a r m ac o v i g i l a n c e  an d  D r u g  
S a f e t y  S o f t w a r e  Ma r k e t :  G lo b a l  I n d u s t r y  T r e n d s ,  S h a r e ,  S iz e ,  G ro w t h ,  O p p o r t u n i t y  
an d  F o r e ca s t  2 02 4 - 2 0 32 , "  t h e  g l o b a l  p h a r ma c o v i g i l a nc e  a nd  d r ug  s a fe t y  s o f t w a r e  
ma r k e t  s i z e  r e a c h ed  U S $  20 2 . 3  M i l l i o n  i n  2 0 2 3 .
Report P ha r m ac o v i g i l a nc e  ( P V )  a n d  d ru g  sa f e t y  so f t w a re  i s  a  m an a g e me n t  s o l u t i o n  t h a t  en a b l e s  t h e  c r e a t i o n ,  c l a s s i f i c a t i o n ,  r e v i e w ,  s u b m i s s i o n ,  a n d  ma i n t en a n c e  o f  P V  d a t a  
an d  ad v e r s e  ev e n t  r e po r t s .  T h e  p r o ce s s  i n v o l v e s  m on i t o r i ng  m e d i c a l  d r u g  e f fe c t s  t o  
Highlight and i d e n t i f y  an d  e xa m i n e  t h e  u n fa v o r a b l e  r ea c t i o n s  o f  t h e  d r u g s .  I t  c re a t e s  m o re  kn o w l e d g e  an d  a w a re n e s s  a m o ng  h e a l t h c a r e  p r o f es s i o n a l s .  
P V  a nd  d r u g  sa f e t y  s o f t w a r e  o f f e r s  s w i f t  s c i e nc e - b a se d  s a fe t y  d e c i s i o n s ,  e n s u re s  
Description g l o ba l  r e g u l a to r y  c o mp l i a n c e ,  i n t e g r a te s  s a f e t y  an d  r i s k  ma n a g em e n t ,  a n d  l o w e r s  t h e  
co s t  o f  P V  p r o c e d u r e s .  A s  a  re s u l t ,  t h e  s o f t w a r e  i s  e x t e n s i v e l y  e m p l o y e d  by  ph a r m a  
an d  b i o t ec h  c om p a n i e s ,  c on t r ac t  r e se a r c h  o r g an i z a t i o ns  ( C R O s ) ,  b u s i ne s s  p r o c e ss  
ou t s o u rc i n g  f i r ms  (B P O s ) ,  a n d  o t h e r  P V  s e r v i c e  p ro v i d e rs .
R eq u e s t  f o r  a  P D F  sa m p le  o f  th i s  r ep o r t :  
h t t p s : / /w w w . i ma r c g r o u p . co m / p ha r m a co v i g i l a n ce - d r ug - s a f e t y - s o f t w a r e - m a r ke t / r eq u e s t s a
mp l e
Report Description
Global  Pharmacov ig i l ance and  Drug  Safety  Sof tware  Market  T rends:
The  marke t  i s  p r imar i l y  d r i ven  by  t he  g row ing  adop t ion  o f  PV  and d rug  sa fe ty  so f tware  by  var ious  c l in i ca l  research  
and ou tsourc ing  compan ies .  The  r i s ing  p reva lence  o f  ch ron ic  d iseases ,  coup led  w i th  the  inc reas ing  inc idence  ra tes  o f  
adve rse  drug  reac t i ons  (ADRs) ,  a re  a lso  fue l ing  t he  g rowt h  o f  t he  marke t .  I n  add i t i on  to  t h i s ,  t he  easy  adop t i on  o f  t he  
so f t ware  due  to  t he  ava i lab i l i t y  o f  cu t t i ng -edge techno logy  i s  a lso  p rope l l i ng  the  marke t  g rowt h .  Governmen ts  ac ross  
va r ious  count r ies  a re  impos ing  s t r i c t  r egu la t ions  f o r  t he  commerc ia l i za t ion  o f  d rugs .  
Consequent l y ,  t he  g row ing  comp lex i t y  re la ted  to  d rug  sa f e t y  regu la t ions  i s  a lso  p rope l l i ng  t he  marke t  g rowt h .  
Fu r the rmore ,  rap id  d ig i t i za t ion  o f  c l i n i ca l  t r i a l s ,  a l ong  w i th  t he  adop t ion  o f  advanced  techno log ies  tha t  improve  
comp l iance  and  p roduc t  sa fe t y  in  PV  and  d rug  sa fe ty  so f tware ,  i s  c rea t ing  a  pos i t i ve  ou t look  f o r  t he  marke t .
Look ing  fo rward ,  the  market  i s  expected  to  reach  a  va lue  o f  US$ 341 . 5  Mi l l ion  by  2032 ,  exh i b i t i ng  a  CAGR o f  
5 . 9% dur ing  the  fo recast  per i od  (2024-2032) .
V i ew Repor t  TOC,  F igures  and Tab l es :  
h t tps : / /www. imarcgroup . com/pharmacov ig i lance-drug -sa fe ty -so f tware-market
Breakup by Functionality:
• Adverse Event Report ing Software
• Drug Safety Audits  Software
• Issue Tracking Software
• Ful ly Integrated Software
Report 
Breakup by Delivery Mode:
Segmentation • On-premises
• Cloud-based
Breakup by End User:
• Pharmaceut ical  and Biotechnology Companies
• Contract  Research Organizat ions
• Business Process Outsourcing Firms
• Others
Breakup by Region:
• North America
Report • Asia-Pacifi c
Segmentation • Europe
• Latin America
• Middle East and Afr ica
• Ab Cube
• Anju Software Inc.
• ArisGlobal  LLC
• Cognizant
Competitive • Ennov Solut ions Inc.
Landscape • Extedo GmbH
• Max Appl icat ion
with Key • Oracle Corporat ion
Players • Sarjen Systems Pvt  Ltd
• Sparta Systems Inc.  (Honeywel l  Internat ional  
Inc.)
• Tata Consultancy Serv ices L imited
• United BioSource LLC
• Wipro L imited.
What was the size of the global pharmacovigilance and drug 
safety software market in 2023?
What is the expected growth rate of the global 
pharmacovigilance and drug safety software market during 
2024-2032?
What has been the impact of COVID-19 on the global 
pharmacovigilance and drug safety software market?
Key 
What are the key factors driving the global 
Questions pharmacovigilance and drug safety software market?
Answered in What is the breakup of the global pharmacovigilance and drug safety software market based on the functionality?
the Report What is the breakup of the global pharmacovigilance and 
drug safety software market based on the delivery mode?
What is the breakup of the global pharmacovigilance and 
drug safety software market based on the end user?
What are the key regions in the global pharmacovigilance 
and drug safety software market?
Who are the key players/companies in the global 
pharmacovigilance and drug safety software market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  P h a r m a c o v i g i l a n c e  a n d  D r u g  S a f e t y  S o f t w a r e  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  F u n c t i o n a l i t y
    6 . 1     A d v e r s e  E v e n t  R e p o r t i n g  S o f t w a r e
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     D r u g  S a f e t y  A u d i t s  S o f t w a r e
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     I s s u e  T r a c k i n g  S o f t w a r e
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
       
 6 . 4     F u l l y  I n t e g r a te d  S o f t w a r e
        6 . 4 . 1  M a r k e t  T r e n d s
        6 . 4 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  D e l i v e r y  M o d e
    7 . 1     O n - p r e m i s e s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     C l o u d - b a s e d
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  E n d  U s e r
Table of     8 . 1     P h a r m a c e u t i c a l  a n d  B i o t e c h n o l o g y  C o m p a n i e s   8 . 1 . 1  Ma r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
Contents     8 . 2     C o n t r a c t  R e s e a r c h  O r g a n i z a t i o n s        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     B u s i n e s s  P r o c e s s  O u t s o u r c i n g  F i r m s
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t
    8 . 4     O th e r s
        8 . 4 . 1  M a r k e t  T r e n d s
        8 . 4 . 2  M a r k e t  F o r e c a s t
9    M a r k e t  B r e a k u p  b y  R e g i o n
    9 . 1     N o r t h  A m e r i c a
        9 . 1 . 1  U n i t e d  S t a te s
           9 . 1 . 1 . 1  M a r k e t  T r e n d s
           9 . 1 . 1 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t io n ,  v i s i t :  
ht tps : / /www. imarcgroup .com/pharmacov ig i lance -d rug -sa fe ty
-so ftware -market / toc
Disclaimer
© 2023  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145 
E-MAIL: [email protected]